Impact of left ventricular hypertrophy on the time-course of renal function in hypertensive patients: A subanalysis of the CASE-J trial

Circulation Journal

Volumn 74, Issue 10, 2010, Pages 2132-2138

  Ueshima, Kenji ^a   Yasuno, Shinji ^a   Oba, Koji ^a   Fujimoto, Akira ^a   Mukoyama, Masashi ^a   Ogihara, Toshio ^b   Saruta, Takao ^c   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; Estimated glomerular filtration rate; Hypertension; Left ventricular hypertrophy

Indexed keywords

AMLODIPINE; CANDESARTAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; JAPANESE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; TIME FACTORS;

EID: 77958043013     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0232     Document Type: Article

References (31)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1): S1-S266.
2. Japanese Society of Nephrology. Chapter 1. Significance of CKD. Clin Exp Nephrol 2009; 13: 192-195.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
4. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
5. Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. J Hypertens 2002; 20: 405-412.
6. Redón J, Cea-Calvo L, Lozano JV, Fernández-Pérez C, Navarro J, Bonet A, et al. ERIC-HTA 2003 Study Investigators. Kidney function and cardiovascular disease in the hypertensive population: The ERIC-HTA study. J Hypertens 2006; 24: 663-669.
7. Nardi E, Palermo A, Mulè G, Cusimano P, Cottone S, Cerasola G. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertension 2009; 27: 633-641.
8. Fesler P, Du Cailar G, Ribstein J, Mimran A. Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 2003; 14: 881-887.
9. Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, et al; RENAAL Investigators. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 2005; 48: 1980-1987.
10. Ueshima K, Yasuno S, Oba K, Fujimoto A, Ogihara T, Saruta T, et al. The effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: A subanalysis of CASE-J trial. Circ J 2009; 73: 1080-1085.
11. Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, et al. Candesartan Antihypertensive Survival Evaluation in JAPAN (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: Rationale, design, and methods. Hypertens Res 2003; 26: 979-990.
12. Ogihara T, Nakao T, Fukui T, Fukiyama K, Ueshima K, Oba K, et al, for the CASE-J Trial Group. Candesartan Antihypertensive Survival Evaluation in Japan trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51: 393-398.
13. Japanese Society of Nephrology. Chapter 9: Evaluation method for kidney function and urinary findings. Clin Exp Nephrol 2009; 13: 209-211.
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
15. Japanese Society of Nephrology. Chapter 2: Definition and classification of CKD. Clin Exp Nephrol 2009; 13: 196.
16. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal Syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
17. Berl T, Henrich W. Kidney-heart interactions: Epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1: 8-18.
18. Grossman W, Jones D, McLaurin P. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 56-64.
19. Ganau A, Devereux RB, Pickering TG, Roman MJ, Schnall PL, Santucci S, et al. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. Circulation 1990; 81: 25-36.
20. Jissho S, Shimada K, Taguchi H, Yoshida K, Fukuda S, Tanaka H, et al. Impact of electrocardiographic left ventricular hypertrophy on the occurrence of cardiovascular events in elderly hypertensive patients: The Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Circ J 2010; 74: 938-945.
21. Ito S, Nagasawa T, Abe M, Mori T. Strain vessel hypothesis: A viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res 2009; 32: 115-121.
22. Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: Subanalysis of the CASE-J Study. Hypertens Res 2009; 32: 505-512.
23. Komatsu H, Yamada S, Iwano H, Okada M, Onozuka H, Mikami T, et al. Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients. Circ J 2009; 73: 2098-2103.
24. Kramer H, Jacobs DR Jr, Bild D, Post W, Saad MF, Detrano R, et al. Urine albumin excretion and subclinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. Hypertension 2005; 46: 38-43.
25. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study: Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143: 319-326.
26. de Andrade TU, Abreu GR, Moysés MR, de Melo Cabral A, Bissoli NS. Role of cardiac hypertrophy in reducing the sensitivity of cardiopulmonary reflex control of renal sympathetic nerve activity in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2008; 35: 1104-1108.
27. Yasuno S, Ueshima K, Oba K, Fujimoto A, Ogihara T, Saruta T, et al. Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial. J Hypertens 2009; 27: 1705-1712.
28. Yilmaz BA, Mete T, Dincer I, Kutlay S, Sengül S, Keven K, et al. Predictors of left ventricular hypertrophy in patients with chronic kidney disease. Ren Fail 2007; 29: 303-307.
29. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347: 1256-1261.
30. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999; 10: 997-1006.
31. Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama K, et al; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: Rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex). Contemp Clin Trial 2009; 30: 97-101.